Loading
A phase 1/2 trial of Garsorasib and IN10018 in advanced solid tumours, run by InventisBio Co., Ltd, active and no longer recruiting.
Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors is a phase 1/2 interventional study registered as NCT05379946 by InventisBio Co., Ltd, with 92 participants enrolled, started 2022-10-12 and due to reach its primary completion in 2027-12-31. Interventions recorded: D-1553 and IN10018.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares InventisBio, IN10018, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares InventisBio, Garsorasib, KRAS & RAS inhibitors, Small-molecule kinase inhibitors and the tag pipeline.
Shares IN10018, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares InventisBio and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares KRAS & RAS inhibitors, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/